1971 to 2017 Saw 32 Drinking Water Hepatitis A Outbreaks
Thirty-two outbreaks of hepatitis A associated with drinking water were identified during 1971 to 2017, and all occurred before 2010.
Viral hepatitis
VIRAL HEPATITIS
Latest Articles
DAA Therapy Benefits Patients With HCV and HCC
Direct-acting antiviral therapy may be a beneficial therapy for patients infected with HCV with a history of hepatocellular carcinoma by increasing overall survival.
Patients With Porphyria Cutanea Tarda Have Higher Mortality Risk
Patients with porphyria cutanea tarda have increased all-cause mortality and risk for death because of gastrointestinal diseases and cancer of the gut, liver, gallbladder, and lungs.
FDA Reports Rare Cases of Liver Injury, Failure With Hep C Therapies
FDA reports rare cases of worsening liver function or liver failure in patients with chronic hepatitis C virus (HCV) who had moderate-to-severe liver impairment and were treated with Mavyret, Zepatier, or Vosevi, despite these drugs being contraindicated in this group of patients.
Kynurenine:Tryptophan Ratio Linked to Liver Fibrosis in Women With HIV, HCV
In people with HIV, the kynurenine/tryptophan (kyn/trp) ratio is elevated and is associated with greater liver fibrosis.
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to peginterferon lambda (Lambda; Eiger BioPharmaceuticals) for the treatment of hepatitis delta virus (HDV) infection.
The FDA has granted Breakthrough Therapy designation to peginterferon lambda (Lambda; Eiger BioPharmaceuticals) for the treatment of hepatitis delta virus (HDV) infection.
USPSTF Advises Broader Age Range for Hep C Screening
Draft recommendation statement expands screening to asymptomatic individuals aged 18 to 79 years
DAAs Cut Deaths in Those Treated for HCV-Related Liver Cancer
Among patients with hepatitis C virus (HCV) infection and complete response to hepatocellular carcinoma (HCC) treatment, direct-acting antiviral (DAA) therapy is associated with a significant reduction in the risk for death.
High Efficacy of Resistance-Guided Retreatment of Patients With Hepatitis C Virus
In Spain, researchers found data from a real-world cohort that showed that retreatment and a sustained viral response, depending upon treatment nonresponse and genotype, can be achieved with certain combinations of direct-acting antivirals.
Lipophilic Statins May Cut Liver Cancer in Chronic Viral Hepatitis
The researchers found that lipophilic statin users had a significantly lower 10-year HCC risk compared with matched nonusers (8.1 versus 3.3 percent; absolute risk difference [RD], −4.8 percent; adjusted subdistribution hazard ratio [aHR], 0.56; 95 percent confidence interval [CI], 0.41 to 0.79), while hydrophilic statin users did not have a lower risk (8.0 versus 6.8 percent; RD, −1.2 percent; aHR, 0.95; 95 percent CI, 0.86 to 1.08).
Liver Stiffness Measurement as a Potential Screening Tool for Liver-Related Events in HCV
Measuring liver stiffness may be a feasible community screening tool to predict liver-related adverse events.
Hospital vs Primary Care Comparison of Treatment Outcomes in Hepatitis C
Researchers in Australia found that treatment with direct acting antivirals for hepatitis C in the primary care setting is effective in treatment uptake in people who inject drugs, compared with referrals to hospital-based services.
HCV, HIV Association With Peripheral Artery Disease Examined
Investigators analyzed the relationship between HIV, hepatitis C virus, and peripheral artery disease in women.
Diabetes and Hepatitis C: A Need for Integrated Pharmacologic Management
Researchers found data that showed hepatitis C virus infection is linked to an increased risk for diabetes mellitus in both chronic hepatitis patients and patients with cirrhosis from hepatitis C.
Less Than One-Third of At-Risk Adults Have Protective Hepatitis B Antibodies
By 2014, less than one-third of individuals aged 18 to 49 years who were at risk for hepatitis B virus exhibited hepatitis B surface antibody levels indicative of protection.
Fibronectin Predicts Seroclearance in Chronic Hepatitis B
Fibronectin may be a potential marker for hepatitis B surface antigen seroclearance.
Lateral Flow Immunoassay to Detect and Manage Chronic Hepatitis B Infection
The novel method of lateral flow immunoassay may be a cost-effective way to identify patients with chronic hepatitis B virus infection.
Oral Fluid Samples Used to Detect Hepatitis B Antibody
Optimized, commercial enzyme immunoassays may be able to diagnose hepatitis B virus using oral fluid samples.
USPSTF Reaffirms Recommendation for HBV Screening HBV During Pregnancy
The United States Preventative Service Task Force has issued a statement that reaffirms its 2009 recommendations for screening pregnant women for hepatitis B virus.
Want to read more?
Please login or register first to view this content.